About the consortium

EUCAPA is a joint effort of three organisations dedicated to advancing healthcare for patients through Health Technology Assessment (HTA) training. The consortium includes the European Organisation for Rare Diseases (EURORDIS), the European Patients’ Forum (EPF), and UMIT TIROL - University for Health Sciences and Technology.

EURORDIS, as the coordinator of the project, is responsible for recruiting and selecting patients, developing the introductory HTA training, and project management. With a network of over 1000 rare disease patient organisations from 74 countries, EURORDIS is uniquely positioned to tailor the training program to the specific needs of patients.
UMIT TIROL - University for Health Sciences and Technology, a leading university in health technology assessment, is responsible for developing the training curricula and conducting the HTA training programs. With a long-standing practice in teaching HTA on a national and international level, UMIT TIROL is ensuring that the training program is of the highest quality and meets the needs of patients.
EPF, an umbrella organisation for patient groups in public health and health advocacy across Europe, is in charge of project communication, promoting the training of patients, and increasing awareness about HTA. It currently represents 80 patient organisations in 19 countries, and an estimated 150 million patients across Europe. By leveraging its extensive experience in patient advocacy and patient engagement, EPF is ensuring that the training program reaches as many patients as possible.

Through the EUCAPA project, we are working to empower patients with the knowledge and skills they need to effectively advocate for themselves and their communities in the complex world of HTA. By providing training in HTA, we aim to increase the involvement of patients in healthcare decision-making and ultimately improve healthcare outcomes.

Stay up to date with our newsletter!

Keep up with the latest updates on patient involvement and HTA.

We care about your data. Read our privacy policy.